GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial!
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants
We were having cocktails at...
GeoVax Labs (GOVX) JP Morgan 2024 Healthcare Conference Transcript.
(Presentation text bolding for emphasis by Editors of the Biotech Stock Review, not the company.
Revive Therapeutics (RVVTF) $0.02, Explores the Use of Bucillamine for Long COVID.
Bucillamine is one of the most amazing drugs (in our opinion), which was repurposed from its original use as an anti-inflammatory for...
Adding GeoVax (GOVX) $3.32 to Reverse Stock Split Watch List.
Okay, Here's Our First Name for the Reverse Stock Split, Watch List. We'll Venture to Have 10 Names Added to Watch List...
Adding Geovax (GOVX) to 2024 Biotech Watch List.
GEOVAX (GOVX) $0.32
We added this to the Watch List earlier in the...
Bridging the Immunity Gap: An In-Depth Conversation with GeoVax’s (GOVX) CEO, David Dodd
In an era of rapid scientific development, the pharmaceutical industry constantly evolves to meet new challenges and seize emerging opportunities. GeoVax, a...
YIKES! New Form of Antimicrobial Resistance Discovered – One of the World’s Greatest Health...
A new mechanism has been discovered that enables bacteria to take up nutrients from their human host and bypass antibiotic treatment. This...
Provention Biosciences (PRVB) Enters the Danger Zone.
Chart Looks Beautiful - But Nervous is why, we use soft and dry.
LIVE QUOTE
We'll...
VERU (VERU) $6.66, Goes Poof.
Veru Provides Update on FDA Advisory Committee Meeting
Market Cap Plunges from...
Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
Latest article
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.
Can You Imagine Selling Solgenix at $2.00 yesterday.
And to be honest, news wasn't all that big - such...
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
When we finished writing our earlier 44-page report,...
